Literature DB >> 31273618

The prognostic role of liver stiffness in patients with chronic liver disease: a systematic review and dose-response meta-analysis.

Yue Shen1, Sheng-Di Wu1, Ling Wu1, Si-Qi Wang1, Yao Chen2, Li-Li Liu1, Jing Li3, Chang-Qing Yang3, Ji-Yao Wang1, Wei Jiang4.   

Abstract

BACKGROUND AND AIMS: Liver stiffness measurement (LSM) by transient elastography (TE) has been assessed for the evaluation of clinically relevant outcomes in patients with chronic liver diseases (CLDs) while with variable results. This systematic review and meta-analysis aims to investigate the relationship between baseline LSM by TE and the development of clinically relevant outcomes.
METHODS: The systematic review identified eligible cohorts reporting the association between baseline LSM by TE and risk of hepatic carcinoma (HCC), hepatic decompensation (HD), all-cause and/or liver-related mortality and liver-related events (LREs) in CLD patients. Summary relative risks (RRs) with 95% confidence intervals (CIs) were estimated using a random-effect model. The dose-response association was evaluated by generalized least squares trend (Glst) estimation and restricted cubic splines. Commands of GLST, MKSPLINE, MVMETA were applied for statistical analysis.
RESULTS: 62 cohort studies were finally included, reporting on 43,817 participants. For one kPa (kilopascal) increment in baseline liver stiffness (LS), the pooled RR (95% CI) was 1.08 (1.05-1.11) for HCC, 1.08 (1.06-1.11) for all-cause mortality, 1.11 (1.05-1.17) for liver-related mortality, 1.08 (1.06-1.10) for HD and 1.07 (1.04-1.09) for LREs. Furthermore, the nonlinear dose-response analysis indicated that the significant increase in the risk of corresponding clinically relevant outcomes turned to a stable increase or a slight decrease with increasing baseline LS changing primarily in the magnitude of effect rather than the direction.
CONCLUSIONS: The dose-response meta-analysis presents a combination between the levels of baseline LS and RRs for each clinically relevant outcome. TE, which is noninvasive, might be a novel strategy for risk stratification and identification of patients at high risk of developing these outcomes.

Entities:  

Keywords:  Cancer; Cirrhosis; Fibroscan; Liver; Outcome

Mesh:

Year:  2019        PMID: 31273618     DOI: 10.1007/s12072-019-09952-5

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  6 in total

1.  Gadobenate dimeglumine-enhanced biliary imaging from the hepatobiliary phase can predict progression in patients with liver cirrhosis.

Authors:  Chenxi Liu; Yan Sun; Yao Yang; Yuemin Feng; Xiaoyu Xie; Lingyu Qi; Keke Liu; Ximing Wang; Qiang Zhu; Xinya Zhao
Journal:  Eur Radiol       Date:  2021-02-03       Impact factor: 5.315

2.  Novel Prognostic Models for Predicting the 180-day Outcome for Patients with Hepatitis-B Virus-related Acute-on-chronic Liver Failure.

Authors:  Ran Xue; Jun Yang; Jing Wu; Zhongying Wang; Qinghua Meng
Journal:  J Clin Transl Hepatol       Date:  2021-05-17

3.  Liver stiffness assessment as an alternative to hepatic venous pressure gradient for predicting rebleed after acute variceal bleed: A proof-of-concept study.

Authors:  Samagra Agarwal; Sanchit Sharma; Abhinav Anand; Deepak Gunjan; Anoop Saraya
Journal:  JGH Open       Date:  2020-11-09

4.  Non-Invasive Assessment of Liver Fibrosis and Steatosis in End-Stage Renal Disease Patients Undergoing Renal Transplant Evaluation.

Authors:  Taseen Syed; Nikita Chadha; Dhiren Kumar; Gaurav Gupta; Richard K Sterling
Journal:  Gastroenterology Res       Date:  2021-08-11

5.  Liver stiffness as surrogate parameter in emergency assessment for inpatient health care utilization.

Authors:  Dominic Kaddu-Mulindwa; Marius von Martial; Angela Thiel-Bodenstaff; Vadim Lesan; Sebastian Ewen; Felix Mahfoud; Frank Lammert; Marcin Krawczyk
Journal:  PLoS One       Date:  2022-04-08       Impact factor: 3.240

6.  Liver stiffness measured by magnetic resonance elastography in early recurrence of hepatocellular carcinoma after treatment: A protocol for systematic review and meta analysis.

Authors:  Huiyan Zhao; Lijun Zhang; Huadong Chen
Journal:  Medicine (Baltimore)       Date:  2021-06-11       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.